What are the uses of Jisandai/Bingtongsha? Scope of indications

Epclusa is currently one of the most widely used oral antiviral drugs for the treatment of chronic hepatitis C (HCV). Its indications cover almost all genotypes of HCV infection and has an obvious "all-genotype" advantage. Jisida is composed of a combination of Sofosbuvir and Velpatasvir. It belongs to the category of direct-acting antiviral drugs (DAA). It inhibits viral replication through dual mechanisms, thereby achieving the goal of sustained virological response. Compared with previous treatment methods, the biggest highlight of G3 is that it no longer relies on traditional interferons and does not need to be combined with ribavirin, making the treatment safer, simpler and better tolerated.

From an indication perspective, Gisanda is widely used to treat patients with chronic hepatitis C infection of all major genotypes 1 to 6, regardless of whether the patient has a background of cirrhosis or not. For some patients with compensated cirrhosis, Gisanda can also be used as the first choice treatment option. In some cases, the drug may also be used in combination with other drugs to achieve better viral clearance in patients with decompensated cirrhosis. For re-treatment patients who have received previous treatment but have not been cured, Gisada is also feasible, especially because its resistance barrier is relatively high and the treatment results are stable.

Another application scenario of Jisanda is its value in certain specific groups of people, such as people with HIV infection, people with renal dysfunction or special groups who cannot tolerate other drugs. Overseas clinical guidelines mostly recommend it as a first-line drug, reflecting the authoritative status of Jisandai in the field of HCV treatment. Since the treatment course is generally 12 weeks, treatment can be initiated without relying on viral genotyping results, further reducing the time cost between diagnosis and treatment.

Reference: https://www.epclusa.com/